These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38515208)

  • 81. Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics.
    Nahleh Z; Otoukesh S; Mirshahidi HR; Nguyen AL; Nagaraj G; Botrus G; Badri N; Diab N; Alvarado A; Sanchez LA; Dwivedi AK
    Cancer Med; 2018 Jun; 7(6):2710-2717. PubMed ID: 29733543
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
    Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
    Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Racial disparities in breast cancer survival: an analysis by age and stage.
    Deshpande AD; Jeffe DB; Gnerlich J; Iqbal AZ; Thummalakunta A; Margenthaler JA
    J Surg Res; 2009 May; 153(1):105-13. PubMed ID: 19084242
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
    Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
    JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.
    Gnerlich JL; Deshpande AD; Jeffe DB; Sweet A; White N; Margenthaler JA
    J Am Coll Surg; 2009 Mar; 208(3):341-7. PubMed ID: 19317994
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hepatocyte growth factor pathway expression in breast cancer by race and subtype.
    Jones GS; Hoadley KA; Olsson LT; Hamilton AM; Bhattacharya A; Kirk EL; Tipaldos HJ; Fleming JM; Love MI; Nichols HB; Olshan AF; Troester MA
    Breast Cancer Res; 2021 Aug; 23(1):80. PubMed ID: 34344422
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
    O'Brien KM; Cole SR; Tse CK; Perou CM; Carey LA; Foulkes WD; Dressler LG; Geradts J; Millikan RC
    Clin Cancer Res; 2010 Dec; 16(24):6100-10. PubMed ID: 21169259
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Genomic profiling of breast cancer in African-American women using MammaPrint.
    Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
    Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer.
    Cho B; Han Y; Lian M; Colditz GA; Weber JD; Ma C; Liu Y
    JAMA Oncol; 2021 Jul; 7(7):1016-1023. PubMed ID: 33983438
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
    Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
    JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.
    Kroenke CH; Sweeney C; Kwan ML; Quesenberry CP; Weltzien EK; Habel LA; Castillo A; Bernard PS; Factor RE; Kushi LH; Caan BJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):689-99. PubMed ID: 24604094
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer.
    Shen T; Brandwein-Gensler M; Hameed O; Siegal GP; Wei S
    Hum Pathol; 2015 Nov; 46(11):1776-84. PubMed ID: 26363528
    [TBL] [Abstract][Full Text] [Related]  

  • 94. An admixture scan in 1,484 African American women with breast cancer.
    Fejerman L; Haiman CA; Reich D; Tandon A; Deo RC; John EM; Ingles SA; Ambrosone CB; Bovbjerg DH; Jandorf LH; Davis W; Ciupak G; Whittemore AS; Press MF; Ursin G; Bernstein L; Huntsman S; Henderson BE; Ziv E; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3110-7. PubMed ID: 19843668
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
    Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial.
    Sadigh G; Gray RJ; Sparano JA; Yanez B; Garcia SF; Timsina LR; Obeng-Gyasi S; Gareen I; Sledge GW; Whelan TJ; Cella D; Wagner LI; Carlos RC
    JAMA Oncol; 2022 Apr; 8(4):579-586. PubMed ID: 35175284
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women.
    Gallagher EJ; Fei K; Feldman SM; Port E; Friedman NB; Boolbol SK; Killelea B; Pilewskie M; Choi L; King T; Nayak A; Franco R; Cruz D; Antoniou IM; LeRoith D; Bickell NA
    Breast Cancer Res; 2020 May; 22(1):40. PubMed ID: 32393319
    [TBL] [Abstract][Full Text] [Related]  

  • 98. AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature.
    Davis M; Tripathi S; Hughley R; He Q; Bae S; Karanam B; Martini R; Newman L; Colomb W; Grizzle W; Yates C
    PLoS One; 2018; 13(6):e0196909. PubMed ID: 29912871
    [TBL] [Abstract][Full Text] [Related]  

  • 99. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.